Cipla USA, Inc. 2026-04-15 Health serious FDA
Health · FDA · Recall #FDA-D-0423-2026
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only,… Recall
Issued April 15, 2026 · Cipla USA, Inc.
In April 2026, Cipla USA, Inc. recalled the Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only,…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
What you should do
- 1 Stop using Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only,… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Cipla USA, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Cipla USA, Inc.
- Category
- Health
- Recall date
- April 15, 2026
- Units affected
- Not reported
- Sold at
- Nationwide in the USA
- Recall number
- FDA-D-0423-2026
- Made in
- United States
- Issuing agency
- FDA
In context
- Cipla USA, Inc. has 9 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 356th Health recall we've logged in 2026.